ArticleBiology direct2026
Inhibiting the Hif-1α-Drp1 axis alleviates mitochondrial dysfunction and reduces senescence-like changes in myocardial tissue after acute myocardial infarction.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCellular senescence is a significant pathological process in acute myocardial infarction (AMI), yet its upstream regulatory mechanisms remain unclear. This study reveals that the HIF-1α /Drp1 signaling axis serves as a critical link between hypoxia and senescence-like changes in myocardial tissue by disrupting mitochondrial homeostasis.
methodsUsing rat AMI model (in vivo) and hypoxia‑exposed H9c2 cardiomyocytes (in vitro), we assessed mitochondrial morphology, mtROS, and senescence markers. Genetic gain‑ and loss‑of‑function approaches were applied to modulate Drp1 and HIF‑1α. We further evaluated the effects of the mitochondrial fission inhibitor Mdivi‑1 and the SASP inhibitor Ruxolitinib on mitochondrial function, senescence, and apoptosis.
resultsAMI/hypoxia activated the ERK1/2-Akt pathway, promoting Drp1 Ser616 phosphorylation and mitochondrial translocation, leading to excessive fission, mtROS burst, and senescence-like changes in myocardial tissue (in vivo) / cardiomyocyte senescence (in H9c2 cells). HIF-1α transcriptionally regulated Drp1 expression. Mdivi-1 restored mitochondrial dynamics, reduced SASP-related inflammation, and improved cardiac function, indicating a myocardial protective effect. Ruxolitinib suppressed Drp1 Ser616 phosphorylation and alleviated senescence, apoptosis, and pyroptosis.
conclusionHIF-1α-mediated upregulation of Drp1 and ERK-dependent phosphorylation of Drp1 collectively drive mitochondrial dysfunction and senescence-like changes in myocardial tissue in AMI. Targeting these pathways or the SASP pathway represents a promising therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.